Infectious disease
Organizations should plan for the worst and hope for the best, ensuring critical research can be continued without risking the safety of employees or the continuity of the company.
Four separate research groups in the U.S., Australia and China analyzed how temperature and humidity affect the coronavirus and they predict that hot summer months could decrease the presence of the virus in the Northern Hemisphere.
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
“Using untested drugs without the right evidence could raise false hope and even do more harm than good and cause a shortage of essential drugs that are needed to treat other diseases,” said WHO Director-General Tedros Adhanom Ghebreyesus.
This morning, the Indianapolis-based company said it will delay most new study starts and pause enrollment in most ongoing studies in light of the COVID-19 pandemic.
In order to continue to provide patients with access to the potential treatment, Gilead said it is in the process of transitioning from individual compassionate use requests to expanded access programs.
Malaria Drug and Antibiotic Combo May Work Against COVID-19, But Experts Warn Caution and Skepticism
French researchers have published an article describing the potential use of a combination of hydroxychloroquine and the antibiotic azithromycin. The U.S. Food and Drug Administration is also evaluating the drugs but have not yet made recommendations.
Insys founder John Kapoor is using the coronavirus pandemic as part of his legal defense to remain out of prison while he appeals his January racketeering conviction.
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
A University of Florida chemistry professor who fled the United States after falling under investigation for his ties to academic institutions in China has been at the forefront of developing a diagnostic test for the novel coronavirus in China.
PRESS RELEASES